Zentalis Doses First Patient in Phase 3 Trial for Platinum-Resistant Ovarian Cancer

Event summary

  • First patient dosed in ASPENOVA Phase 3 trial of azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer.
  • Trial compares azenosertib to standard-of-care chemotherapy in a global, randomized study.
  • DENALI Phase 2 trial expected to read out by year-end 2026, potentially supporting accelerated approval.
  • ASPENOVA trial designed to confirm clinical benefit and support full approval conversion.
  • Azenosertib dose of 400mg QD 5:2 selected based on DENALI Part 2a interim analysis.

The big picture

Zentalis is advancing azenosertib through a dual-track regulatory strategy, aiming to address a significant unmet need in platinum-resistant ovarian cancer. The Phase 3 ASPENOVA trial and ongoing DENALI Phase 2 trial reflect a biomarker-driven approach to identify patients most likely to benefit from this targeted therapy. The collaboration with global clinical trial groups underscores the recognition of the urgent need for effective treatments in this underserved population.

What we're watching

Regulatory Pathway
Whether DENALI Phase 2 data will meet FDA requirements for accelerated approval by year-end 2026.
Clinical Execution
The pace at which ASPENOVA trial enrolls 420 patients and delivers confirmatory data for full approval.
Market Differentiation
How azenosertib's oral, targeted approach compares to standard chemotherapy in Cyclin E1-positive patients.